EUVIMEDEUVIMED entdecken
Übersichtsarbeit

CDK4/6-related inhibitors from a medicinal chemistry perspective: Research advances in the past six years (2020–2025)

Cunqin Wang, Yanhua Zhang, Shuyun Bao, Xiaojun Huang, Cheng Wang, Yonglei Zhang

Bioorganic Chemistry · 2026-11 · 183 · 110565

DOI: 10.1016/j.bioorg.2026.110565 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioorganic Chemistry, 2026-11. Verfasst von Cunqin Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Wannan Medical College, Wuhu 241002, China; Anhui Provincial Engineering Research Center for Polysaccharide Drugs, Anhui Provinci…. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit nennt 216 Literaturangaben. Gefördert von: Wannan Medical College, Jinan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cyclin-dependent kinase 4/6 (CDK4/6), as an important kinase regulating cell cycle progression, exhibits functional abnormalities closely associated with the initiation and progression of various cancers. Consequently, targeted inhibition of CDK4/6 represents a valuable and promising therapeutic strategy for cancer treatment. To date, multiple CDK4/6 inhibitors have been approved for market release and have demonstrated significant clinical efficacy. However, these drugs exhibit limited therapeutic versatility and carry substantial adverse effects. In recent years, significant progress has been made through systematic structural optimization of existing CDK4/6 inhibitors and the development of novel CDK4/6 inhibitors, such as dual-target inhibitors based on CDK4/6. This review aims to systematically summarize the research progress of CDK4/6 inhibitors over the past six years, focusing on their structural features, design strategies, and biological activity. Finally, we also discusses in detail the challenges and future directions for the discovery of CDK4/6-targeting drugs in cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsAntineoplastic AgentsHumansMolecular StructureChemistry, PharmaceuticalStructure-Activity RelationshipNeoplasms

Stichwörter der Autor:innen

CDK4/6SARSmall molecule inhibitorscancer

Substanzen

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsCDK4 protein, humanAntineoplastic AgentsCDK6 protein, human

Autor:innen und Institutionen

  • School of Pharmacy, Wannan Medical College, Wuhu 241002, China; Anhui Provincial Engineering Research Center for Polysaccharide Drugs, Anhui Provincial Engineering Laboratory for Screening and Re-evaluation of Active Co…
  • State Key Laboratory of Bioactive Molecules and Drugg ability Assessment, Jinan University, China.
  • School of Pharmacy, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi 330031, People's Republic of China. Electronic address: wangcheng@ncu.edu.cn.

Förderung

  • Wannan Medical College
  • Jinan University

Zitieren

APA

Wang, C., Zhang, Y., Bao, S., Huang, X., Wang, C., & Zhang, Y. (2026). CDK4/6-related inhibitors from a medicinal chemistry perspective: Research advances in the past six years (2020–2025). Bioorganic Chemistry, 183, 110565. https://doi.org/10.1016/j.bioorg.2026.110565

Vancouver

Wang C, Zhang Y, Bao S, Huang X, Wang C, Zhang Y. CDK4/6-related inhibitors from a medicinal chemistry perspective: Research advances in the past six years (2020–2025). Bioorganic Chemistry. 2026;183:110565. doi:10.1016/j.bioorg.2026.110565

BibTeX
@article{Wang2026,
  author = {Wang, Cunqin and Zhang, Yanhua and Bao, Shuyun and Huang, Xiaojun and Wang, Cheng and Zhang, Yonglei},
  title = {CDK4/6-related inhibitors from a medicinal chemistry perspective: Research advances in the past six years (2020–2025)},
  journal = {Bioorganic Chemistry},
  year = {2026},
  volume = {183},
  pages = {110565},
  doi = {10.1016/j.bioorg.2026.110565}
}
Kostenlos starten →